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Abstract
Background:  Reports on childhood cancer survivors estimated cumulative probability of
developing secondary neoplasms vary from 3,3% to 25% at 25 years from diagnosis, and the risk of
developing another cancer to several times greater than in the general population.
Methods: In our retrospective study, we have used the classification tree multivariate method on
a group of 849 first cancer survivors, to identify childhood cancer patients with the greatest risk
for development of secondary neoplasms.
Results: In observed group of patients, 34 develop secondary neoplasm after treatment of primary
cancer. Analysis of parameters present at the treatment of first cancer, exposed two groups of
patients at the special risk for secondary neoplasm. First are female patients treated for Hodgkin's
disease at the age between 10 and 15 years, whose treatment included radiotherapy. Second group
at special risk were male patients with acute lymphoblastic leukemia who were treated at the age
between 4,6 and 6,6 years of age.
Conclusion: The risk groups identified in our study are similar to the results of studies that used
more conventional approaches. Usefulness of our approach in study of occurrence of second
neoplasms should be confirmed in larger sample study, but user friendly presentation of results
makes it attractive for further studies.
Background
As the number of childhood cancer survivors grows and
the period of follow-up lengthens, increasing attention is
directed towards the delayed adverse effects of therapy.
The late effects of treatment on many organs have been
described. These include the, cardiovascular, skeletal,
endocrine, dental, hepatic, pulmonary and renal systems.
Psychosocial, educational and neuropsychological prob-
lems are also common, but among the most serious of the
delayed complications is the appearance of second neo-
plasms (SN). The better the treatment results become for
the primary malignancy, the more may long-term results
be compromised by secondary cancers [1]. Relevant
reports of the cumulative probability of developing SN
vary from 3.3% to 25% at 25 years from diagnosis. Thus,
the risk of developing another cancer can be up to 35
times greater than in the general population [2].
SNs develop after interaction among many independent
factors to which the patient is exposed before, during and
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after treatment of the first malignancy. Some of those fac-
tors may have synergistic oncogenic effects on the devel-
opment of SNs, and design of prospective studies to
identify those risk factors is difficult, due to the long
latency period. In our retrospective study, we have used
the decision tree multivariate method to identify the
group of childhood cancer patient with the greatest risk
for development of SN.
Methods
Patients
The study included 1577 cancer patients younger than 16
years of age registered at the Cancer Registry of Slovenia in
the period from 1-1-1961 to 12-10-2000. The decision
tree analysis was performed on a group of 849 first cancer
survivors, among whom 34 developed a SN. An SN was
defined as a malignant neoplasm in a new location that
was neither the result of direct spread nor a metastasis
from the primary neoplasm. Also included among the SNs
was a neoplasm in the same location as the primary but of
different histological type [3]. Primary neoplasms were
categorized according to histology as: leukemia, Hodg-
kin's disease, non-Hodgkin lymphoma, Ewing sarcoma,
osteogenic tumors, nephroblastoma, neuroblastoma,
hepatoblastoma, rhabdomyosarcoma, retinoblastoma,
thyroid cancer, germ-cell tumors, tumors of central nerv-
ous system (CNS) and others. The group of "others" con-
sisted of carcinomas of different organ systems in 41 cases
and two melanomas. They were grouped together because
each particular group was too small for further analysis.
Data in the database included patient's name, sex, date of
birth, clinical diagnosis, histologic type of the neoplasm,
date of the diagnosis, treatment modality, date and status
at the last follow-up. Detailed information on chemother-
apy and radiotherapy was not included in the database.
Table 1 presents the independent and dependent variables
used for multivariate analysis.
All data were collected through the childhood cancer fol-
low-up program in Slovenia. One pediatric-oncology
center in the Department of Pediatrics, University Medical
Center, Ljubljana, serves as a national referral center for all
pediatric patients with malignant diseases. It covers the
population of Slovenia that approximates 2 million. After
the end of treatment all children are followed in the center
until the end of schooling or for at least four years. After
that, they are followed at the outpatient Clinic for Late
Effects at the Institute of Oncology. A team there, headed
by an oncologist known to the patient as a member of the
pediatric follow-up team, continues follow-up for life [4].
Fewer than 5% of patients were lost to follow-up because
of permanent migration outside the territory of the
Republic Slovenia. All of them were treated before 1990.
The study was performed in compliance with the Helsinki
Declaration with the approval N° 38/11/96 of National
Medical Ethics Committee of Slovenia
Classification tree analysis
Classification tree is a method for multivariate analysis
that allow for study of simultaneous influence of a series
of independent variables on the one dependent variable.
The analysis is performed by successive divisions of the
original group of cases into pairs of subgroups, where
each division is based on the value of a single independ-
ent variable. The variable that produces most pure pair of
case subgroups is chosen for a division (division being
often referred to as a split). A purity of a case group is
measured as a fraction of cases with the same value of the
dependent variable: a completely pure group contains
cases that have the same outcome. Each of subgroup in
the pair becomes a parent group in the next step of the
analysis and is therefore further divided in the same way.
The division of cases stops when the group of cases is com-
pletely pure or when it contains less than operator-
defined minimal number of cases. In our study, the C4.5
[5] program for building classification trees was used.
C4.5 allows the setting of several parameters that influ-
ence the branching and quality of final classification tree:
most notably there is one parameter that determines the
smallest number of cases to be included in a single group
(mentioned already above), and another parameter that
Table 1: Description and values of the independent variables and the dependent variables (last row) used for multivariate analysis.
Variable name Description
Sex male (485), female (346)
age_at_diagnosis numeric
histology_type (categories) leukemia, Hodgkin's disease, non-Hodgkin lymphoma, Ewing sarcoma, 
osteogenic tumors, nephroblastoma, neuroblastoma, hepatoblastoma, 
rhabdomyosarcoma, retinoblastoma, thyroid cancer, germ-cell tumors, 
tumors of central nervous system, others
Surgery yes (481), no (368)
Radiotherapy yes (500), no (349)
Chemotherapy yes (598), no (251)
second_neoplasm yes (34), no (815)BMC Cancer 2007, 7:27 http://www.biomedcentral.com/1471-2407/7/27
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determines the degree of post-pruning performed. For
details please refer to the description in [5]. The optimal
values of these parameters were determined using a stand-
ard cross-validation method [6-8]. Following this
method, we systematically try different combinations of
parameter settings and use cross-validation to estimate the
performance of the tree on unseen cases, and choose the
settings that lead to the best tree performance. Using these
optimal settings, we build a tree that is then used in fur-
ther analysis and present in next section. We tried 5 possi-
ble values for the minimal number of cases in a group
parameter (from 1 to 5) and 7 possible values for post-
pruning confidence (1, 5, 10, 25, 50, 75, and 99%), which
lead to 5 × 7 = 35 possible parameter settings.
The usual performance measure for classification trees is
the accuracy of the tree when predicting the outcome (the
value of the dependent variable) on samples not seen dur-
ing the process of tree building. Note however, that since
the SN has been observed in only a minority of patients
(about 4%), the classification tree algorithm tend to build
a single group of cases that classify all the patients as non-
SN cases, this simple tree have a prediction accuracy of
96% that can not be significantly improved. This tree
however misclassifies all the patients where SN is
observed as non-SN cases. Note that this misclassification
is much more serious for the patient when the opposite
one, where a non-SN patient is predicted to have SN. The
tool to deal with this issue in classification trees is to
assign different costs to misclassifications, i.e., specifying
that misclassifying a SN patient as a non-SN case is X time
worse (or more costly) than the misclassifying a patient in
opposite direction, where X is a user-specified parameter.
In business applications of classification trees, misclassifi-
cations can be easily related to costs and these can be then
used to estimate the X parameter setting. However, in our
case, this is non-trivial issue: we know that this X is larger
than 1. Thus, we approach this problem using the cross-
validation procedure outlined above: we use it to find
optimal settings for the X parameter. We choose the
parameter that lead to minimal number of misclassifica-
tions of a SN patient as a non-SN case. In the experiments
with C4.5, we increase the cost of this misclassification
type using 7 different settings, starting with the default
one of 1:1 (equal costs of both misclassifications),
through 1:5, 1:10, 1:25, 1:50, 1:100, and 1:200.
Note finally, that since we use an alternative performance
criterion, the classification tree obtained the cross-valida-
tion procedure outlined above is not expected to provide
accurate classification of cases into SN and non-SN
classes. Instead of using the tree as an accurate predictor,
we are interested in analyzing the tree structure and iden-
tifying the risk groups where incidence of SN is signifi-
cantly higher than the one observed in the whole
population of 849 cancer survivors included in the study.
Results
Highly branched tree, where most of the cases are misclas-
sified, may be result of low rate of events or low predicta-
bility of the factors used to develop the tree. In the analysis
of the entire group of 1577 childhood cancer patients, the
Table 2: Comparison of classification results obtained using cross-validation for three different C4.5 parameter settings.
Misclassification cost setting 5:1, post-pruning confidence 1%
Classified as
Observed SN Non-SN
SN 0 34
Non-SN 0 815
Misclassification cost setting 10:1, post-pruning confidence 1%
Classified as
Observed SN Non-SN
SN 8 26
Non-SN 66 749
Misclassification cost setting 25:1, post-pruning confidence 50%
Classified as
Observed SN Non-SN
SN 31 3
Non-SN 18 797
The settings comprise of three different misclassification costs, two different post-pruning confidence values, and the default value of 2 for the 
minimal number of cases in a group parameter. In each table, the number of SN patients being misclassified as non-SN is typed in bold-face. To 
induce the final tree, presented in Figure 1, we selected a parameter setting that lead to minimal number of such misclassifications.BMC Cancer 2007, 7:27 http://www.biomedcentral.com/1471-2407/7/27
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number of SN cases is below 3% and all the SN cases were
classified as non-SN cases. Therefore we reduced our anal-
ysis on the group of children who survived their first can-
cer. There were 849 patients in this group and 34
developed SN. We have build several classification tree
models with different misclassification costs in the algo-
rithm. We considered misclassification of an SN case in
the group without SN as a more severe mistake than vice
versa. In the extreme case, with misclassification cost 5:1,
we have built a tree where all SN cases were allocated in
the group without SN. On the other side, if the misclassi-
fication cost was set too high, there were too many cases
without SN classified as patients with SN. Table 2 presents
a sample of classification results obtained using three dif-
ferent parameter settings. The table includes results for the
optimal parameter setting, where the misclassification
cost value was set to 25:1, post-pruning confidence value
to 50% and minimal number of cases in a group to 2.
On the basis of these results presented in Table 2, we were
able to choose the parameter setting that gave the lowest
number of SN cases being misclassified as non-SN cases.
Figure 1 depicts the classification tree obtained using this
parameter setting.
Despite the optimal setting, branching of the tree is still
considerable. There are many sets with individual SN
cases and some clusters in which misclassified non-SN
cases predominate. In the graphic presentation of the
pruned tree the first factor that divides our cohort is radi-
otherapy. In the group of patients treated without radio-
therapy, only 1,4% patients developed SN, which is
considerable less than in the group of irradiated patients
(5,8%). From this point we can follow two paths. The first
one encompasses patients with Hodgkin's disease. At the
end of the non-Hodgkin's disease branch, a group of
females, aged between 10 and 15 years at first diagnosis
and treated with chemotherapy, can be identified as a
group in which the risk of an SN reaches 45%. The other
path reveals a group of male patients with acute leukemia,
who were aged between 4.6 and 6.6 years of diagnosis of
leukemia. In these groups the risk for SN reaches 40%.
Both incidence rates of 40% and 45%, observed in these
groups of patients, are significantly higher compared to
the observed 4% incidence in the whole population. The
Clasification tree for the risk of secondary neoplasm after treatment for childhood cancer Figure 1
Clasification tree for the risk of secondary neoplasm after treatment for childhood cancer. Analysis of 849 childhood cancer 
survivors from Cancer Registry of Slovenia.
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fact that can be easily confirmed using a simple ChiS-
quared test, see Table 3 for results.
Discussion and conclusion
In general the estimation of risk varies, between hospital
based and population based studies [2], probably due to
more complete follow-up in the former registries. Our
population based study, differs from similar studies also
for defining a period at risk for SMN, from the diagnosis
of primary cancer on. Varying cure rates in different time
periods also have impact on estimated risk. The period
covered in our study starts in early seventies, when cure
rate of childhood cancer was still very low.
In our study of 849 childhood cancer survivors we have
performed a multivariate analysis using classification trees
to identify groups that are at special risk for the develop-
ment of a SN. The group at highest risk was identified as
girls with Hodgkin's disease, aged between 10 and 16
years at first diagnosis, who were treated with combined
of chemo- and radio-therapy. In all of this cases, the SN
was a carcinoma, with the latent period ranging from 3 to
16.5 years after treatment of the Hodgkin's disease. These
results are similar to the observation of Beaty et. al. [9],
who found statistically significant higher risk for SN in
adolescents treated for Hodgkin's disease. Bhatia and cow-
orkers found 6.7 fold higher risk for SN in patients treated
for Hodgkin's disease between 10 and 16 years of age [10].
They also found the risk for secondary solid tumors after
a combination of chemotherapy and radiotherapy to be
twice as great as after chemotherapy without radiother-
apy. It is possible that some tissues are particularly vulner-
able to the carcinogenic effect of chemotherapy and
radiotherapy during puberty.
The challenge is to maintain the high rate of cure in Hodg-
kin's disease and at the same time reduce the risk for sec-
ond malignancies. Some modern protocols of treatment
of Hodkin's disease have already reduced or completely
omitted radiotherapy for patients with low stages of dis-
ease. Löning et. al found radiation therapy as significant
risk factor for SN after treatment of childhood acute lym-
phoblastic leukemia [11]. This is in contrast with the
results of Dalton et. al. [12]. Löning also states that partic-
ularly young children are at increased risk when irradia-
tion has been used. Intensive chemotherapy regimens do
not predict a higher risk as reported in several studies
[13,14]. In the Childhood Cancer Survivor Study, the
diagnosis of leukemia was independently associated with
the occurrence of a second malignant tumor of the central
nervous system, as was younger age at diagnosis [15].
The improved survival rate of children with cancer should
not be overshadowed by the incidence of SNs. Nonethe-
less, patients and health care providers should be aware of
the populations at greatest risk for this serious complica-
tion, and focus their efforts on primary and secondary pre-
vention in this vulnerable population. Using the C 4.5
algorithm for building classification trees, we were able to
construct subgroups at different risk, by logical combina-
tion of patients characteristics. The risk groups identified
in our study are similar to the results of studies that used
more conventional approaches. In contrast to traditional
regression methods (e.g. Cox proportional hazard regres-
sion) which compute prognostic index as a weighted aver-
age of patients' characteristics, in the classification tree
model the subgroups are based directly on the patients'
characteristics. The model shows the correlation between
the various independent variables and its influence on the
Table 3: Comparison of SN incidence in the two risk groups, identified using the classification tree from Figure 1, with the incidence of 
SN in the whole observed population
First identified risk group (girls with Hodgkin's lymphoma): ChiSquared p-value is much smaller than 0.01 (in a range of 10-11)
Group of patients SN Non-SN Total
Identified risk group 5 6 11
Others 29 809 838
All included in the study 34 815 849
Second identified risk group (boys with acute lymphoblastic leukemia): ChiSquared p-value is much smaller than 0.01 (in a range 
of 10-9)
Group of patients SN Non-SN Total
Identified risk group 4 6 10
Others 30 809 838
All included in the study 34 815 849
ChiSquared test show significant difference in both cases.BMC Cancer 2007, 7:27 http://www.biomedcentral.com/1471-2407/7/27
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end result [16]. Another advantage of the method is in its
simple and intuitive nature (i.e. find the best split by
examining all possible splits in all available variables,
form subgroups based on this split, repeat in all sub-
groups) [17].
Classification trees have been used in medical and health
care applications for more than 20 years and have been
shown to be a powerful classification tool in various areas
[18]. In oncology the method has been used for tumor
classification, evaluation of biomarkers [19-23]. The sam-
ple size represents a limitation in our study, but the
method used is a potentially powerful tool for investigat-
ing multilevel interactions [24]. Occurrence of secondary
neoplasms may well be the result of complex interactions
of several independent factors such as genetic predisposi-
tion, treatment related factors and environmental expo-
sures. The approach to the analyses of a larger sample here
described might serve to validate the technique.
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